SomaServe's PolyNaut platform addresses the ‘delivery problem’. Reaching the site of action is one of the most pressing challenges in the advancement of gene therapy and the development of protein therapeutics for intracellular targets.
Using polyNaut technology we are uniquely able to address the shortcomings of viral or lipid-based delivery technologies by encapsulating a range of therapeutic modalities into polymer nanovesicles that can penetrate the blood brain barrier effectively and selectively target different tissues and cell types.
Through partnership and internal development we are deploying PolyNaut to develop a next generation of gene therapies and intracellular proteins in oncology, immunology and CNS disorders.
Company Details
- Founded
- -
- Address
- Cambridge , Cambs Cb22 3at, Gb
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- somaserve.com
- HQ
- Cambridge , Cambs
Somaserve Questions
Somaserve's website is somaserve.com
Somaserve's LinkedIn profile is https://uk.linkedin.com/company/somaserve
Somaserve's industry is
Biotechnology Research
Somaserve's top competitors are
Maxion Therapeutics,
Vectory,
Storm Therapeutics Limited,
Camgene Therapeutics,
Abzena,
T-Therapeutics Ltd,
Phoremost Ltd,
Unity Campus,
Vianautis,
Pl Bioscience Gmbh.
Somaserve's categories are Biotechnology Research
Somaserve's founding year is 2018
